You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1297-ESGO A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial

Citation Tools

Article menu

Download PDFPDF

Endometrial cancer
2022-RA-1297-ESGO A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Oaknin A, Pothuri B, Gilbert L, et al
2022-RA-1297-ESGO A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial
International Journal of Gynecologic Cancer 2022;32:A141-A142.